Row
T
TGTXAI Stock Diagnostic Report
TG Therapeutics down 11% following Q2 bottom line miss
TG Therapeutics' stock price fell by 11% due to a shortfall in expected net income for the second quarter.
View Source Article ↗AI CATALYST SCORE40 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time